Disclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
|
|
- Oliver Baker
- 8 years ago
- Views:
Transcription
1 TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis Janssen Pharmaceuticals Off-label use may be mentioned: dabigatran, rivaroxaban, apixaban, edoxaban, FEIBA, Kcentra Anticoagulant Therapy What are the options? 1930s heparin 1950s warfarin 1990s Low molecular weight heparin 1990s direct thrombin inhibitors 2000s factor Xa inhibitor 2010s TSOACs More new drugs are coming... 1
2 Warfarin (Coumadin ) Dosing Roulette Oral Gold Standard Rat Poison? Warfarin (Coumadin ) Action: inhibits vitamin K dependent clotting factors factors VII, IX, X, II Half Life: hours (avg:40hrs) it takes days to reach steady-state Monitoring: PT/INR Home monitoring finger stick devices Dosing: dependent on INR INR Goal: 2-3 usual ( other) Cost- generic $4/month Warfarin (Coumadin ) Indications: Prophylaxis and treatment for VTE and thromboembolic disorders, adjunct to reduce risk of systemic embolism such as recurrent MI or stroke Antidote: Vitamin K (phytonadione) Available as oral tablets Subcutaneous route is preferred injection route IM route should be avoided due to risk of hematoma formation May be given IV for life-threatening bleeding Administer IV slowly not to exceed 1mg/min Dilute 10mg dose in 50ml saline over 20 min Does not work immediately! VTE= venous thromboembolism (DVT-deep vein thrombosis &/or PE-pulmonary embolism) 2
3 Warfarin (Coumadin ) Food/nutrient interactions Examples: Foods high in vitamin K Dark green leafy vegetables Nutritional supplements Ensure, Boost, Slim Fast, Carnation instant breakfast Vitamins, minerals, herbals Alcohol (Et 2 OH) Acute ingestion- increase INR Chronic ingestion- decrease INR EtOH-related liver diseaseincrease INR Independently increases hemorrhagic risk Partial List of Anticoagulant Drugs Under Development Dabigatran Pradaxa (Boehringer Ingelheim) Edoxaban Savaysa (Daiichi Sankyo) Rivaroxaban Xarelto (Janssen) Apixaban Eliquis (Bristol-Myers Squibb / Pfizer) Weitz JI et al. Chest
4 VTE prophylaxis (THR, TKR) Non- Valvular Afib (NVAF) Approval History Dabigatran Rivaroxaban Apixaban Europe Mar 2008 Canada Jun 2008 Canada Oct 2010 USA Oct 2010 Europe Aug 2011 VTE treatment Canada Sep 2014 USA Apr 2014 Europe Jun 2014 Europe Sep 2008 Canada Sep 2008 USA July 2011 USA Nov 2011 Europe Dec 2011 Canada Jan 2012 Europe Dec 2011 Canada Feb 2012 USA Nov 2012 Europe May 2011 Canada Mar 2012 USA Mar 2014 Europe Nov 2012 Canada Dec 2012 USA Dec 2012 Europe Jul 2014 Canada Sep 2014 USA Aug 2014 Edoxaban was approved Jan 2015 in US for NVAF and VTE treatment; Canada - Nov 2013 for NVAF Summary of Major Clinical Trials VTE prophylaxis VTE treatment NVAF REMODEL REMOBILIZE RENOVATE RENOVATE 2 RECORD 1 RECORD 2 RECORD 3 RECORD 4 ADVANCE 1 ADVANCE 2 ADVANCE 3 STARS J4 & J5 STARS J5 RECOVER REMEDY RESONATE RECOVER 2 EINSTEIN-DVT EINSTEIN-EXT EINSTEIN-PE AMPLIFY AMPLIFY-EXT Hokusai VTE Dabigatran Rivaroxaban Apixaban RELY RELYABLE ROCKET-AF ARISTOTLE AVERROES ENGAGE AF Edoxaban FDA Approved Indications As of February, 2015 Dabigatran Rivaroxaban Apixaban Edoxaban VTE prophylaxis (THR, TKR) x x Nonvalvular Afib VTE treatment 4
5 Pharmacokinetics Dabigatran Rivaroxaban Apixaban Edoxaban Target Thrombin Factor Xa Factor Xa Factor Xa Peak Effect (h) Half-life (h) ~ (14-17 elderly) (11-13 (28 severe elderly) renal) Dosing Frequency Twice daily Daily* Twice daily Daily Clearance 80% Renal 20% Biliary 66% Renal 34% Biliary 25% Renal 75% Biliary 50%Renal 50%Biliary * Despite short half-life, once daily dosing possible due to persistence of anti-xa activity Harder S, Graff J. Eur J Clin Pharmacol 2013; 69(9): Renal Dosing Dabigatran Non-valvular Afib : >50 ml/min 150mg po BID ml/min (+dronedarone or ketoconazole) 75mg po BID ml/min 75mg po BID <15 ml/min no recommendations VTE treatment: >30 ml/min 150mg po BID (after 5-10 days of parenteral anticoagulation) (if crcl<50 ml/min and is receiving P-gp inhibitor, then avoid coadministration) <30 ml/min no recommendations Hemodialysis: no recommendations Note hemodialysis removes ~57% over 4 hours Renal Dosing Rivaroxaban Postoperative thromboprophylaxis (TKR,THR): >30 ml/min 10mg po daily <30 ml/min not recommended Non-valvular Afib: >50 ml/min 20mg po daily ml/min 15mg po daily <15 ml/min not recommended VTE treatment: >30 ml/min 15mg po BID x 21 days, then 20mg po daily <30 ml/min not recommended Hemodialysis: Avoid use in this population 5
6 Renal Dosing Apixaban Postoperative thromboprophylaxis (TKR,THR) 2.5mg po BID beginning 12-24hrs post-op (note: patients with significant, impaired, CrCl<30 ml/min were excluded from clinical trials) Non-valvular Afib: 5mg po BID unless two of the following exist: creatinine >1.5mg/dl; age >80 years; weight <60 kg then 2.5mg po BID VTE treatment: 10mg po BID x 7 days, then 5mg po BID (note: patients with Cr>2.5 or CrCl<25 ml/min were excluded from clinical trials) NVAF indication: ESRD requiring hemodialysis 5mg po BID; reduce to 2.5mg BID if age>80 yrs or weight <60 kg Renal Dosing Edoxaban Non-valvular Afib: >95 ml/min DO NOT USE ml/min 60mg po daily ml/min 30mg po daily <15 ml/min no information VTE treatment: >50 ml/min 60mg po daily (following 5-10days of parenteral anticoagulant) 15-50ml/min or <60kg or concomitant P-gp inhibitor 30mg po daily Hemodialysis: does not significantly contribute to clearance Drug Interactions Dabigatran and edoxaban interact with drugs that affect the transporter P-glycoprotein (P-gp) Rivaroxaban and apixaban also interact with P- gp drugs, as well as those that affect the microsomal enzyme CYP3A4 Examples Ketoconazole Rifampicin Cyclosporine Itraconazole Clarithromycin Tacrolimus Amiodarone Protease inhibitors Carbamazepine Verapamil St. John s wort Phenytoin Increased risk of major bleeding seen in studies of all 3 drugs when used with anti-platelet agents Schulman S, Crowther MA. Blood 2012; 119(13): Harder S, Graff J. Eur J Clin Pharmacol 2013; 69(9):
7 PT / INR aptt Thrombin Time Other Laboratory Monitoring Dabigatran Rivaroxaban Apixaban Increases with dose Very insensitive Increases with dose Not linear, plateaus Most sensitive Normal TT = no drug Too sensitive Ecarin clotting time is the best assay, but is not widely available PT / INR and aptt are both prolonged, but to a varying degree, and depend upon the reagents used No effect Anti-Xa assay can be used, but must be standardized to the drug No effect Anti-Xa assay very similar to LMWH, and may not need to re-calibrate? Non-valvular Atrial fibrillation VTE Prophylaxis VTE Treatment Non-valvular Atrial fibrillation RE-LY (Connolly SJ et al. NEJM 2009; 361: ) N = 18,113 (mean CHADS 2 =2.1) Dabigatran 150 mg bid vs. warfarin Superior in efficacy when warfarin avg TTR 64% Similar rates of major bleeding Dabigatran associated with less ICH Significantly more GI bleeding MUST TAKE WITH FOOD! Baumann-Kreuziger LM, et al. J Trauma Acute Care Surg
8 Non-valvular Atrial fibrillation ROCKET AF (Patel MR et al. NEJM 2011; 365:883-91) N = 14,264 (mean CHADS 2 =3.5) Rivaroxaban 20 mg daily vs. warfarin Rivaroxaban was non-inferior to warfarin No overall difference in major bleeding Rivaroxaban associated with less ICH and fatal bleeding, but more GI bleeding Take with evening meal Non-valvular Atrial fibrillation ARISTOTLE (Granger CB et al. NEJM 2011; 365:981-92) N = 18,201 (mean CHADS 2 =2.1) Apixaban 5 mg bid vs. warfarin Apixaban was superior in preventing stroke with less overall bleeding and lower all cause mortality Apixaban associated with less ICH No increase in GI bleeding ENGAGE AF-TIMI 48 Non-valvular Atrial fibrillation (Giugliano RP NEJM 2013; 369: ) N = 21,105 (mean CHADS 2 =2.8+1) Edoxaban 60 mg daily vs. warfarin Edoxaban was non-inferior in preventing stroke Edoxaban was associated with less ICH More GI bleeds Increase rate of ischemic stroke with CrCl>95ml/min 8
9 VTE Prophylaxis (THR, TKR) Rivaroxaban Apixaban vs. Enoxaparin Equal or better efficacy Similar bleeding risk Advantage of oral administration Both agents have been trialed for VTE prophylaxis in medically ill patients and were associated with unacceptable rates of bleeding VTE Treatment Dabigatran Rivaroxaban Apixaban vs. Conventional therapy Edoxaban Non-inferior to warfarin, with same or less overall bleeding risk Less major bleeding (eg. ICH) Edoxaban & dabigatran require 5-10 days of overlap with parenteral anticoagulant Time in Therapeutic Range (INR ) RE-MEDY = 65% EINSTEIN = 58% EINSTEIN-PE = 63% AMPLIFY = 61% Hokusai VTE=65.6% Management of Bleeding Dabigatran Rivaroxaban Apixaban Antidote None None None Activated charcoal* Dialysis Yes Yes Yes ~35% protein bound ~60% removed in 2-3 h ** Highly protein bound Dialysis ineffective * Activated charcoal indicated within 2 3 hours of drug ingestion ** Dabigatran has a very large volume of distribution (60 70 L); expect multiple dialysis sessions to be required Highly protein bound Dialysis ineffective 9
10 Hemostatic Agent Options for Management of Bleeding Name Category Available in US? Aminocaproic acid antifibrinolytic Yes Tranexamic acid antifibrinolytic Yes Profilnine, Bebulin 3 factor PCC Yes Cofact, Kanokad 4 factor PCC No Octaplex, Kaskadil 4 factor PCC, + PC, PS No Beriplex / Kcentra 4 factor PCC, + PC, PS Yes FEIBA Activated PCC Yes NovoSeven rfviia Yes (None are approved in the US for this indication) Use of Factor Concentrates for Management of Bleeding Factor Concentrates are NOT antidotes They create hypercoagulability Specific reversal agents are in trials Thrombotic risk is significant! Hospitals have in house protocols but there are no specific guidelines available Should be restricted for LIFE THREATENING bleeding only! Antidotes in development: Aripazine (PER977), Andexanet (PRT064445), Idarucizumab (BI ) 10
11 Drug Dabigatran Rivaroxaban Edoxaban Apixaban Perioperative Management Package Insert Recommendations For CrCl >50, stop 1 to 2 days prior For CrCl <50, stop 3 to 5 days prior Consider longer* if major surgery, spinal puncture, spinal or epidural catheter Stop at least* 24 hours prior Stop at least* 48 hours prior (moderate or high risk procedures) Stop at least* 24 hours prior (low risk procedures) Lab testing If TT (dabigatran) or anti-xa (rivaroxaban, apixaban) are normal, drug has cleared. If tests are abnormal there is still drug on board but cannot quantitate risk *Clinical decisions should be individualized based on patient parameters that could influence clearance and risk of bleeding versus risk of clotting Advantages Direct anticoagulants Predictable pharmacokinetics No bridging needed* No monitoring needed Few diet / drug interactions *most indications Disadvantages Renal / hepatic excretion No antidotes Unable to monitor directly Limited experience Lack of long-term safety data To use or not to use? Non-valvular Atrial Fibrillation Those already on warfarin, with good INR control, have little to gain by switching New agents may have better safety profile (less intracranial hemorrhage) Consider patient compliance and cost of drug and testing Drug interactions with the new agents and drugs for afib, etc. must be considered 11
12 To use or not to use? Prevention of VTE Dabigatran and edoxaban are not approved in the US for this indication Rivaroxaban and apixaban are good alternatives to LMWH / warfarin in this setting Look closely at the trial comparator dose of enoxaparin before chosing agent Approval currently only for THR and TKR To use or not to use? Treatment of VTE Special attention should be given to dosing regimens when prescribing/counseling Patients may no longer require hospitalization but should have careful follow-up Rivaroxaban and apixaban are also indicated for extended treatment of VTE after at least 6 months of treatment but more bleeding than placebo To use or not to use? We need more experience in patients with: Malignancy Pregnancy Mechanical heart valves Thrombophilia (APC, PC, PS, AT double heterozygotes or homozygotes for FVL/PGM) Extremes of body weight Those with more than low bleeding risk Real world compliance (not on studies) RE-ALIGN Study (NEJM 2013; 369: ) Dabigatran vs. warfarin Aortic and mitral valves Terminated early due to EXCESS thromboembolic and bleeding events in dabigatran group 12
13 Take Home Points The new oral anticoagulants are not necessarily better than warfarin; they are different, and each has advantages and disadvantages Careful patient selection is crucial for the safe use of TSOACs Management of bleeding complications from the TSOACs is a major clinical challenge; we have no guidelines and real world clinical experience is limited QUESTION? COMMENTS? DISCUSSION? 13
Novel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationNovel Anticoagulants
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationClinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationManagement of Bleeding and Practical Management of New Oral Anticoagulants
Management of Bleeding and Practical Management of New Oral Anticoagulants Anna Rahmani October 2, 2014 CONFLICT OF INTEREST:! NONE Overview: Background on the new oral anticoagulants (NOACs) Approved
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationAnticoagulation Strategies: Are New Oral Anticoagulants Ready for Prime Time? B. Gail Macik, MD Professor of Medicine & Pathology
Anticoagulation Strategies: Are New Oral Anticoagulants Ready for Prime Time? Virginia American College of Physicians Annual Conference March 7, 2014 B. Gail Macik, MD Professor of Medicine & Pathology
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More informationThe New Era of Anticoagulation
The New Era of Anticoagulation Nedaa Skeik, MD, FACP, FSVM, RPVI Associate Professor of Medicine Section Head, Vascular Medicine Medical Director, Thrombophilia/Anticoagulation Clinic Medical Director,
More information9/14/2015. Disclosures. Learning Objectives. Clinical Case. What s in a name? NOAC Uses and Indications
NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AND THEIR IMPACT ON THE OBSERVATION UNIT! Carol Lynn Clark MD MBA FACEP Associate Director of Research Department of Emergency Medicine Beaumont Health
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationAnticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice. B. Gail Macik, MD Professor of Medicine & Pathology
Anticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice Virginia Association of Hematology & Oncology Spring Meeting April 18, 2015 B. Gail Macik, MD Professor of Medicine
More informationIt s a. of Anticoagulation. Objectives
It s a New World of Anticoagulation LAURA B. RICHARDSON, PHARMD, BCPS-CV CLINICAL PHARMACIST ABBOTT NORTHWESTERN HOSPITAL Objectives Understand the key differences between the oral anticoagulants t Become
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationDisclosure: Dr. Smith has no actual or potential conflict of interest associated with this presentation.
Disclosure: Dr. Smith has no actual or potential conflict of interest associated with this presentation. Michael Smith, Pharm. D., BCPS, CACP Pharmacy Clinical Manager William Backus Hospital You were
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationMore information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
More information